Physician profile
James Feld
NPI 1942228630
$667.22
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $613 · 2020: $53.73.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $234.76 | 2019 | |
| Merck Sharp & Dohme LLC | $127.20 | 2019-2020 | |
| Pfizer INC. | $53.94 | 2019-2020 | |
| Therapeuticsmd, INC. | $52.11 | 2019 | |
| Novo Nordisk INC | $35.22 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.78 | 2019 | |
| Lilly USA, LLC | $26.19 | 2019-2020 | |
| Amarin Pharma, INC. | $19.65 | 2019 | |
| Aytu Biopharma, INC. | $18.01 | 2019 | |
| Sanofi Pasteur INC. | $16.60 | 2019 | |
| Astellas Pharma US INC | $16.59 | 2019 | |
| Novartis Pharmaceuticals Corporation | $16.14 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.10 | 2019 | |
| Seqirus USA INC | $10.93 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Feld listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.